Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02238522
Title Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Zenith Epigenetics Corp.
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.